SciTransfer
EAVI2020 · Project

Next-Generation HIV Vaccine Candidates Ready for Industry Development Partners

healthPrototypeTRL 4Thin data (2/5)
eavi2020.org

Imagine trying to find the right key for a lock that keeps changing shape — that's what developing an HIV vaccine is like. This project brought together 27 top research groups from 12 countries to test dozens of possible vaccine designs in small human trials, picking the best performers. They focused on two main defense strategies: training killer cells to destroy infected cells, and training the body to produce antibodies that block the virus. After 7 years, they narrowed down the most promising candidates and built new tools to predict which vaccines are most likely to succeed in large-scale trials.

By the numbers
35 million
People living with HIV globally
>2 million
New HIV infections per year
30 years
Prior HIV vaccine research without success
27
Research partners in consortium
12
Countries represented
The business problem

What needed solving

HIV/AIDS affects 35 million people worldwide with over 2 million new infections every year, yet after 30 years of research no effective vaccine exists. The core business problem is that promising vaccine candidates keep failing in expensive late-stage clinical trials, wasting billions in development investment. The industry needs better methods to identify winners early and kill losers fast.

The solution

What was built

The project delivered optimized T cell vaccine regimens (selected for breadth, potency, and durability of cellular response) and optimized humoral vaccine regimens (selected for breadth, potency, and durability of induced antibodies). They also developed risk prediction methods to reduce the chance of late-stage vaccine failure.

Audience

Who needs this

Large pharma companies with HIV/infectious disease vaccine pipelinesBiotech startups developing next-generation vaccine platformsContract research organizations running vaccine clinical trialsDiagnostics companies building immune monitoring assaysGlobal health organizations funding HIV prevention programs
Business applications

Who can put this to work

Biotechnology & Vaccine Manufacturing
enterprise
Target: Biotech companies developing infectious disease vaccines

If you are a biotech firm looking to expand your vaccine pipeline beyond COVID — this project identified and validated multiple HIV vaccine candidate regimens through human experimental medicine studies. With 30 years of prior HIV vaccine failures informing their risk-reduction methods, these optimized immunogen-adjuvant-vector combinations could accelerate your own development timeline. The consortium tested both T cell and antibody-based approaches, giving you multiple entry points.

Contract Research & Clinical Development
mid-size
Target: CROs specializing in vaccine and immunology trials

If you are a contract research organization running vaccine clinical trials — this project developed rapid iterative experimental medicine study designs that test vaccine candidates faster and cheaper than traditional Phase I approaches. Their methods for predicting late-stage failure risk could save your pharma clients millions by killing bad candidates early. The consortium's experience across 12 countries provides multi-site trial infrastructure knowledge.

Diagnostics & Immunoassay Development
SME
Target: Companies developing immune response measurement tools

If you are a diagnostics company building immunoassay platforms — this project created validated methods to measure both cellular and humoral immune responses to HIV vaccine candidates, assessing breadth, potency, and durability. These assay protocols and benchmarks could be licensed or adapted for your immune monitoring products. With over 2 million new HIV infections per year, the testing market remains substantial.

Frequently asked

Quick answers

What would it cost to license or co-develop these vaccine candidates?

The project data does not include licensing terms or development cost estimates. As a Research and Innovation Action coordinated by Imperial College London with 27 partners, IP arrangements would need to be negotiated through the consortium. Early-stage vaccine candidates typically require significant further investment for Phase II/III trials.

How close are these vaccines to industrial-scale manufacturing?

These are early-stage candidates — the project focused on discovery, selection, and small experimental medicine human studies, not manufacturing scale-up. The deliverables describe 'up-selection of optimal regimens' based on breadth, potency, and durability, meaning the best candidates have been identified but large-scale production processes are not yet developed.

Who owns the intellectual property from this research?

IP ownership sits with the 27-partner consortium led by Imperial College London. With 3 industry partners and 2 SMEs involved, commercial licensing pathways likely exist. Specific IP terms would need to be discussed with the coordinator, as RIA projects typically allow partners to retain IP from their contributions.

What regulatory pathway would these vaccine candidates follow?

HIV vaccine candidates follow standard EMA/FDA regulatory pathways for biological products. The project used experimental medicine studies (small human trials) which generate early clinical safety and immunogenicity data. Moving to Phase II/III would require regulatory submissions based on this data, plus manufacturing process validation.

What is the timeline from current status to a marketable product?

Based on available project data, the candidates are at the selection and early human testing stage. HIV vaccines historically require 5-10+ years from this point to reach market, given the complexity of the virus. The project's risk prediction methods were specifically designed to reduce late-stage failure, which could shorten timelines compared to previous HIV vaccine efforts.

Can these vaccine technologies be applied to other diseases?

The project developed platform technologies including immunogen design, adjuvant-vector combinations, and prime-boost scheduling methods. Based on the project objective, these approaches could potentially be adapted for other difficult viral targets. The consortium includes groups with broad vaccine discovery expertise across 12 countries.

Consortium

Who built it

The EAVI2020 consortium is research-heavy: 27 partners across 12 countries, dominated by universities (10) and research organizations (12), with only 3 industry players and 2 SMEs (11% industry ratio). This signals deep scientific capability but limited commercial pull. Imperial College London leads as coordinator, lending strong academic credibility. The inclusion of partners from outside the EU (Australia, Canada, US) reflects the global nature of HIV vaccine research. For a business partner, the low industry involvement means there may be fewer competing commercial claims on the IP, but also that significant commercialization infrastructure would need to be built or brought in from outside the consortium.

How to reach the team

Imperial College of Science Technology and Medicine (UK) — contact through university technology transfer office or project website

Order a report on this consortiumSee IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE profile →
Next steps

Talk to the team behind this work.

Want to explore licensing or co-development of these HIV vaccine candidates? SciTransfer can connect you with the right consortium partner and provide a detailed technology brief.

Order a report on this topicMore in Health & Biomedical
More in Health & Biomedical
See all Health & Biomedical projects →
Automated Allergy Test Covering All Allergens in One Run, Ready to Ship
AllergyExplorer
Open →
Lab-Sized 3D Cell Microscope Replaces 12-Month Waits at Giant Synchrotron Facilities
LICENT
Open →
Blood Test Platform That Catches Rare Diseases Early Using AI-Powered Diagnostics
METAdiag
Open →